Patients with current deep vein thrombosis or deep vein thrombosis within the past months are not eligible STEP I: Patients may have a history of current or previous deep vein thrombosis or pulmonary embolism but must be willing to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulation Have had a prior thrombotic event (e.g., pulmonary embolism, deep vein thrombosis) or are currently receiving therapeutic or prophylactic doses of anticoagulants. History of deep vein thrombosis and/or pulmonary embolus within months of study entry Presence of deep vein thrombosis based on screening lower extremity Doppler ultrasonography. History of blood clots, pulmonary embolism, or deep vein thrombosis unless on adequate anticoagulant therapy as determined by the treating investigator (subject must be on stable dose for weeks). Patient must not have any thromboembolic event (deep vein thrombosis or pulmonary embolism) less than weeks prior to enrollment Deep vein thrombosis or pulmonary embolism =< weeks before first dose of protocol-indicated treatment, unless adequately treated and stable.\r\n* Patients receiving therapeutic non-coumarin anticoagulation are eligible, provided they are on a stable dose (per investigator judgment) of anticoagulant. A diagnosis of deep vein thromboses in the preceding four weeks of study enrollment. Have been treated for a deep vein thrombosis, pulmonary embolism, myocardial infarction, or ischemic stroke within the past months (may be extended to year if medically indicated per physician discretion). History of symptomatic deep vein thrombosis or pulmonary embolism within months of enrollment. have a history of venous thromboembolism, including deep vein thrombosis, pulmonary embolism or retinal vein thrombosis, unless currently on anticoagulant therapy; History of symptomatic deep vein thrombosis or pulmonary embolism within months of enrollment Prior or concurrent deep vein thrombosis or pulmonary embolism Patients who have a history of deep vein thrombosis or pulmonary embolus and are stable on anticoagulation for > month are eligible History of deep vein thrombosis or pulmonary embolism within month of anticipated starting of axitinib Patients with active pulmonary embolism or deep vein thrombosis (diagnosed within days of\r\nstudy enrollment) Myocardial infarction, uncontrolled angina, congestive heart failure, or cerebrovascular accident within previous months; subjects with a history of deep vein thrombosis or pulmonary embolism, at provider discretion Any of the following in the previous months: deep vein thrombosis or symptomatic pulmonary embolism History of deep vein thrombosis or pulmonary embolism requiring systemic anticoagulation within months before enrollment significant cardiovascular disease within the last months: including myocardial infarction, unstable angina, congestive heart failure, ongoing arrhythmias of Grade > , thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism). Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed. Patients with a recent history of deep vein thrombosis or pulmonary embolus, in the six months prior to enrollment are not eligible for this study Patients with any of the following within months of enrollment: deep vein thrombosis, pulmonary embolus, myocardial infarction, cerebrovascular accident, unexplained loss of consciousness Deep vein thrombosis or pulmonary embolism within months of study entry History of deep vein thrombosis and/or pulmonary embolism within weeks of enrollment. Deep vein thrombosis or pulmonary embolism =< weeks before first dose of protocol-indicated treatment, unless adequately treated and stable History of vascular disease (e.g. deep vein thrombosis, stroke) Acute deep vein thrombosis or clinically relevant pulmonary embolism, not stable for at least weeks prior to first IMP administration. Patients must not have a history of prior stroke, transient ischemic attack (TIA), pulmonary embolism, or untreated deep vein thrombosis\r\n* NOTE: Patients may be eligible if they have received at least months of anticoagulation for a deep vein thrombosis History of deep vein thrombosis or pulmonary embolism within months of screening; patients who are currently taking anticoagulation therapy for a prior history (> months from screening) of thrombosis may still be eligible History of blood clots, pulmonary embolism, or deep vein thrombosis in previous months unless controlled by anticoagulant treatment Prior history of a major thrombotic event, such as pulmonary emboli, deep vein thrombosis or stroke, as assessed by the investigator, or history of an asparaginase associated serious hemorrhage or thrombus requiring anticoagulation therapy History of pulmonary embolus and/or substantial deep vein thrombosis Patients may have a history of current or previous deep vein thrombosis or pulmonary embolism but are required to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulation Has had within the past months the occurrence of one or more of the following events: myocardial infarction, cerebrovascular accident, deep vein thrombosis, pulmonary embolism, hemorrhage (NCI CTCAE Grade or ), chronic liver disease (meeting criteria for Child-Pugh Class B or C), or organ transplantation. Has a history of deep vein thrombosis or pulmonary embolism within months of screening. History of symptomatic deep vein thrombosis or pulmonary embolism within months of enrollment. Conditions contraindicated to progesterone treatment (including, but not limited to, thrombophlebitis, deep vein thrombosis, pulmonary embolus, clotting or bleeding disorders, heart disease, diabetes, history of stroke, allergy to peanuts, hypersensitive to progesterone and liver dysfunction) Known, existing uncontrolled coagulopathy; patients who have had a venous thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis) requiring anticoagulation are eligible IF: they are appropriately anticoagulated and have not had a grade or greater bleeding episode in the weeks before day Has a history of blood clots, pulmonary embolism, or deep vein thrombosis unless controlled by anticoagulant treatment (patient must be on stable dose for weeks). History of blood clots, pulmonary embolism, or deep vein thrombosis unless controlled by anticoagulant treatment. Have had a new pulmonary embolism, extremity deep venous thromboembolism, or portal vein thrombosis within months of study enrollment (any thrombosis within months of study enrollment must be approved by the protocol chair and/or medical monitor) In past months: deep vein thrombosis or pulmonary embolism Known history of deep vein thrombosis or pulmonary embolus except in patients where the cause was directly related to foreign body implants, i.e. central venous catheters, portacaths, etc. Patients with active pulmonary embolism or deep vein thrombosis (diagnosed within days of study enrollment) Venous thromboembolic events (e.g., deep vein thrombosis or pulmonary embolism) within months of screening Candidates may have a history of deep vein thrombosis, pulmonary embolism, and/or cerebrovascular accident, or require concomitant systemic anticoagulation, if otherwise deemed to be suitable for RP Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, arterial thrombosis) within months prior to enrollment. Documented deep vein thrombosis within year before enrollment on the study, except if upper arm thrombosis related to central venous catheters, within months before enrollment on the study Deep vein thrombosis in the preceding months. Unstable pulmonary embolism, deep vein thrombosis, or other significant arterial/venous thromboembolic event =< days before enrollment Patients with active pulmonary embolism or deep vein thrombosis (diagnosed within days of study enrollment) Pulmonary embolism, deep vein thrombosis, or other significant venous event =< weeks before enrollment Evidence of hepatic vein invasion or caval thrombosis Has had within the past months the occurrence of one or more of the following events: myocardial infarction, cerebrovascular accident, deep vein thrombosis, pulmonary embolism, hemorrhage (CTC Grade or ), chronic liver disease (meeting criteria for Child-Pugh Class B or C), a second active malignancy (excluding basal cell carcinoma and cervical carcinoma in situ), organ transplantation. Have a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolic event during the months prior to receiving study drugs. Occurrence of deep vein thrombosis within weeks, prior to study entry Thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, arterial thrombosis) within months of screening Deep vein thrombosis diagnosed within months History within months of deep vein thrombosis, pulmonary embolism, or stroke Patients with a history of deep vein thrombosis or thromboembolism within < months prior to starting study treatment Prior or concurrent deep vein thrombosis or pulmonary embolism No thrombotic event within months (deep vein thrombosis, pulmonary embolism) of registration for protocol therapy. History of deep vein thrombosis or pulmonary embolism. Patients with a history of deep vein thrombosis or thromboembolism within < months prior to starting study treatment Patients who have had a deep vein thrombosis or pulmonary embolus within the past months are eligible if they are on stable therapeutic anticoagulation Suspected or diagnosed deep vein thrombosis or painful foot neuropathy. Active deep vein thrombosis in the treatment extremity History of thrombosis, deep vein thrombosis, pulmonary emboli, or embolic stroke AND have not been stable on anticoagulants within the past months; local central line thrombosis is allowed Within the past months:\r\n* Acute pulmonary embolus\r\n* Deep vein thrombosis CONTROL (HEALTHY) GROUP: Within the past months:\r\n* Acute pulmonary embolus\r\n* Deep vein thrombosis Conditions that could cause swelling (e.g., pregnancy, congestive heart failure, chronic/acute renal disease, cor pulmonale, nephrotic syndrome, nephrosis, liver failure or cirrhosis, pulmonary edema, and thrombophlebitis, or deep vein thrombosis in arms History of blood clots (i.e. pulmonary embolism, deep vein thrombosis [DVTs]) History of deep vein thrombosis or pulmonary embolism within weeks of first study dose History of: Thrombophelitis, Deep vein thrombosis, Pulmonary embolus, Clotting disorder, Bleeding disorder, Heart disease, Diabetes, Stroke, Peanut allergy, Liver dysfunction, Hypersensitivity to progesterone Patients with thrombosis within the splenic vein Symptomatic deep vein thrombosis or pulmonary embolism within last months No thrombotic event within months (deep vein thrombosis, pulmonary embolism) of starting IFN gamma History of deep vein thrombosis or pulmonary embolism. Participants requires the use of warfarin (use in prophylactic doses [example, deep vein thrombosis prophylaxis]) is allowed.